Five more biotechs file their SEC pa­per­work as the IPO Class of 2021 swells to 60

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter last week’s flur­ry of IPO ac­tion end­ed with two pric­ings and a SPAC deal, sev­er­al biotechs got in on the ac­tion be­fore the long hol­i­day week­end.

In ad­di­tion to the two small­er fil­ings that took place on Fri­day, five oth­er biotechs sent their pa­per­work to the SEC. Four of those com­pa­nies — Verve Ther­a­peu­tics, Cen­tu­ry Ther­a­peu­tics, Am­brx Bio­phar­ma and Cyteir Ther­a­peu­tics — have writ­ten in $100 mil­lion as their ini­tial place­hold­er, while HCW Bi­o­log­ics jot­ted down $50 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA